{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:40:12Z","timestamp":1792521612987,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate cancer-control outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients receiving Lutetium-177 Prostate-Specific Membrane Antigen-617 (Lu-177-PSMA) radioligand therapy according to initial baseline tumor characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We relied on the FRAMCAP (FRAnkfurt Metastatic Cancer Database of the Prostate) database to assess progression-free survival (PFS) and overall survival (OS) in patients receiving Lu-177-PSMA as first to seventh mCRPC therapy line, according to initial time of metastasis (synchronous vs. metachronous), tumor grading (Gleason score [GS] 6\u20137 vs. 8\u201310) and M-stage (M1a vs. M1b vs. M1c) at initial metastatic hormone-sensitive prostate cancer (mHSPC). Kaplan-Meier curve analyses and multivariable Cox regression models were applied; multivariable models are additionally adjusted for ECOG status and line of Lu-177-PSMA therapy (1\u20132\u00a0L vs. 3\u00a0L vs. 4\u20137\u00a0L).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 344 Lu-177-PSMA mCRPC patients, 198 (58%) had synchronous vs. 146 (42%) metachronous mHSPC, 87 (29%) vs. 107 (62%) GS 6\u20137 vs. 8\u201310 and 15 (10%) vs. 121 (81%) vs. 13 (9%) M1a vs. M1b vs. M1c mHSPC disease. No significant differences were observed in PFS (12.1 vs. 13.0 months) or OS (14.9 vs. 18.3 months) between synchronous and metachronous patients (both p\u2009&gt;\u2009=\u20090.09), or in PFS (12.9 vs. 11.8 months) and OS (21.4 vs. 15.1 months) between GS 6\u20137 and GS 8\u201310 (both p\u2009&gt;\u2009=\u20090.3). M-stage-stratified analyses showed an OS difference (17.9 vs. 17.7 vs. 9.0 months for M1a vs. M1b vs. M1c,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), but not for PFS (11.9 vs. 9.5 vs. 8.2 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.08). After multivariable adjustment including ECOG status and treatment line, initial timing of metastasis, GS, and M-stage were not independently associated with PFS or OS. However, later treatment line was independently associated with worse OS (3\u00a0L vs. 1\u20132\u00a0L: HR 2.40, 95% CI 1.14\u20135.04,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021; 4\u20137\u00a0L vs. 1\u20132\u00a0L: HR 4.01, 95% CI 1.83\u20138.80,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) as well as worse ECOG status (1\u20132 vs. 0: HR 2,60, 95% CI 1.38-4,91,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort of mCRPC patients treated with Lu-177-PSMA, initial timing of metastatic disease, Gleason score, and M-stage were not independently associated with PFS or OS after multivariable adjustment including ECOG status and treatment line. These observational findings should not be interpreted as evidence of equivalent treatment efficacy across subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-026-06849-5","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:41:54Z","timestamp":1792474914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics"],"prefix":"10.1007","volume":"44","author":[{"given":"Mike","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh Chi","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Siech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Hoeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Happel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Preisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian C.","family":"Kriegmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K. H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Groener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"4","key":"6849_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2217\/fon.11.23","volume":"7","author":"S Oudard","year":"2011","unstructured":"Oudard S (2011) TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol 7(4):497\u2013506. https:\/\/doi.org\/10.2217\/fon.11.23","journal-title":"Future Oncol"},{"issue":"21","key":"6849_CR2","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"issue":"8","key":"6849_CR3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJMc1107198","volume":"365","author":"C Parker","year":"2011","unstructured":"Parker C, Sartor O (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 365(8):767. https:\/\/doi.org\/10.1056\/NEJMc1107198","journal-title":"N Engl J Med"},{"issue":"13","key":"6849_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197. https:\/\/doi.org\/10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"issue":"5","key":"6849_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa1405095","journal-title":"N Engl J Med"},{"issue":"24","key":"6849_CR6","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla M, Reijke T, Tienhoven GV et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516\u20132527. https:\/\/doi.org\/10.1056\/NEJMoa0810095","journal-title":"N Engl J Med"},{"issue":"9","key":"6849_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","volume":"34","author":"KN Chi","year":"2023","unstructured":"Chi KN, Sandhu S, Smith MR et al (2023) Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol Off J Eur Soc Med Oncol 34(9):772\u2013782. https:\/\/doi.org\/10.1016\/j.annonc.2023.06.009","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"6849_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S et al (2024) Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol 25(1):99\u2013107. https:\/\/doi.org\/10.1016\/S1470-2045(23)00529-6","journal-title":"Lancet Oncol"},{"key":"6849_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.euros.2024.06.010","volume":"66","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Siech C, Hoeh B et al (2024) Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients. Eur Urol Open Sci 66:46\u201354. https:\/\/doi.org\/10.1016\/j.euros.2024.06.010","journal-title":"Eur Urol Open Sci"},{"issue":"26","key":"6849_CR10","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R Wit","year":"2019","unstructured":"Wit R, Bono J, Sternberg CN et al (2019) Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 381(26):2506\u20132518. https:\/\/doi.org\/10.1056\/NEJMoa1911206","journal-title":"N Engl J Med"},{"issue":"12","key":"6849_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, Bono J, Chi KN et al (2021) Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"issue":"8","key":"6849_CR12","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1097\/RLU.0000000000004222","volume":"47","author":"D Has Simsek","year":"2022","unstructured":"Has Simsek D, Kuyumcu S, Karadogan S et al (2022) Outcome of 177 Lu-PSMA radionuclide treatment in advanced prostate cancer and its association with clinical parameters\u202f: a single-center experience. Clin Nucl Med 47(8):e521\u2013e528. https:\/\/doi.org\/10.1097\/RLU.0000000000004222","journal-title":"Clin Nucl Med"},{"issue":"9","key":"6849_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14014","volume":"53","author":"L Giovanella","year":"2023","unstructured":"Giovanella L, Garo ML, Cuzzocrea M, Paone G, Herrmann K (2023) Prognostic role of early prostate specific antigen changes after [177 Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: a meta-analysis. Eur J Clin Invest 53(9):e14014. https:\/\/doi.org\/10.1111\/eci.14014","journal-title":"Eur J Clin Invest"},{"key":"6849_CR14","doi-asserted-by":"publisher","first-page":"e2400645","DOI":"10.1200\/PO-24-00645","volume":"8","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Koll F, Hoeh B et al (2024) Cancer-control outcomes of patients with metastatic castration-resistant prostate cancer with BRCA gene or tumor suppressor mutations undergoing 177-lutetium prostate-specific membrane antigen radioligand therapy. JCO Precis Oncol 8:e2400645. https:\/\/doi.org\/10.1200\/PO-24-00645","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"6849_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2217\/fon.13.39","volume":"9","author":"C Buonerba","year":"2013","unstructured":"Buonerba C, Pond GR, Sonpavde G et al (2013) Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol Lond Engl 9(6):889\u2013897. https:\/\/doi.org\/10.2217\/fon.13.39","journal-title":"Future Oncol Lond Engl"},{"issue":"8","key":"6849_CR16","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1007\/s12094-019-02274-w","volume":"22","author":"J Valero","year":"2020","unstructured":"Valero J, Peleteiro P, Henr\u00edquez I et al (2020) Age, Gleason score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of the Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR). Clin Transl Oncol 22(8):1378\u20131389. https:\/\/doi.org\/10.1007\/s12094-019-02274-w","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"6849_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.euf.2021.04.003","volume":"8","author":"M Wenzel","year":"2022","unstructured":"Wenzel M, W\u00fcrnschimmel C, Nocera L et al (2022) Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis. Eur Urol Focus 8(2):399\u2013408. https:\/\/doi.org\/10.1016\/j.euf.2021.04.003","journal-title":"Eur Urol Focus"},{"issue":"12","key":"6849_CR18","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/pros.23645","volume":"78","author":"E Francini","year":"2018","unstructured":"Francini E, Gray KP, Xie W et al (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78(12):889\u2013895. https:\/\/doi.org\/10.1002\/pros.23645","journal-title":"Prostate"},{"issue":"11","key":"6849_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.urolonc.2024.06.016","volume":"42","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Hoeh B, Kopf P et al (2024) Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer. Urol Oncol 42(11):371. https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.016","journal-title":"Urol Oncol"},{"issue":"5","key":"6849_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102158","volume":"22","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Lutz M, Hoeh B et al (2024) Influence of tumor characteristics and time to metastatic disease on oncological outcomes in metachronous metastatic prostate cancer patients. Clin Genitourin Cancer 22(5):102158. https:\/\/doi.org\/10.1016\/j.clgc.2024.102158","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"6849_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2967\/jnumed.124.268807","volume":"66","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Koll F, Hoeh B et al (2025) Real-world comparison of cabazitaxel versus 177Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer. J Nucl Med Off Publ Soc Nucl Med 66(1):61\u201366. https:\/\/doi.org\/10.2967\/jnumed.124.268807","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"6849_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07076-7","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Hoeh B, Siech C et al (2025) Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-025-07076-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"6849_CR23","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.7150\/thno.108963","volume":"15","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Siech C, Garcia CC et al (2025) Cancer-control outcomes with [177Lu] Lu-PSMA radioligand therapy in elderly, frail or comorbid mCRPC patients. Theranostics 15(7):2672\u20132679. https:\/\/doi.org\/10.7150\/thno.108963","journal-title":"Theranostics"},{"issue":"6","key":"6849_CR24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00259-023-06119-1","volume":"50","author":"N Mader","year":"2023","unstructured":"Mader N, Ngoc CN, Kirkg\u00f6ze B et al (2023) Extended therapy with [177Lu] Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 50(6):1811. https:\/\/doi.org\/10.1007\/s00259-023-06119-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"6849_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"issue":"4","key":"6849_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352\u2013360. https:\/\/doi.org\/10.1056\/NEJMoa1704174","journal-title":"N Engl J Med"},{"issue":"11","key":"6849_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.urolonc.2024.06.016","volume":"42","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Hoeh B, Kopf P et al (2024) Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer. Urol Oncol Semin Orig Investig 42(11):371. https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.016","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"1","key":"6849_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/UPJ.0000000000000471","volume":"11","author":"G Gebrael","year":"2024","unstructured":"Gebrael G, Sayegh N, Tripathi N et al (2024) Impact of initial timing of metastatic disease on survival in patients with newly diagnosed metastatic castration-resistant prostate cancer treated with androgen receptor pathway inhibitors. Urol Pract 11(1):32\u201335. https:\/\/doi.org\/10.1097\/UPJ.0000000000000471","journal-title":"Urol Pract"},{"issue":"7suppl","key":"6849_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/jco.2015.33.7_suppl.212","volume":"33","author":"S Akamatsu","year":"2015","unstructured":"Akamatsu S, Lynch K, Black P et al (2015) The impact of time to metastasis on survival in treatment-na\u00efve prostate cancer patients. J Clin Oncol 33(7suppl):212\u2013212. https:\/\/doi.org\/10.1200\/jco.2015.33.7_suppl.212","journal-title":"J Clin Oncol"},{"issue":"7","key":"6849_CR30","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00345-018-2236-4","volume":"36","author":"S Frees","year":"2018","unstructured":"Frees S, Akamatsu S, Bidnur S et al (2018) The impact of time to metastasis on overall survival in patients with prostate cancer. World J Urol 36(7):1039\u20131046. https:\/\/doi.org\/10.1007\/s00345-018-2236-4","journal-title":"World J Urol"},{"issue":"1","key":"6849_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-022-03861-2","volume":"21","author":"PV Nuzzo","year":"2023","unstructured":"Nuzzo PV, Pederzoli F, Saieva C et al (2023) Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med 21(1):1\u20137. https:\/\/doi.org\/10.1186\/s12967-022-03861-2","journal-title":"J Transl Med"},{"issue":"12","key":"6849_CR38","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Seitz AK, Weinzierl FX et al (2022) Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up. Eur J Nucl Med Mol Imaging 49(12):4262\u20134270. https:\/\/doi.org\/10.1007\/s00259-022-05853-2","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06849-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06849-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06849-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:01:57Z","timestamp":1792519317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06849-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6849"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06849-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mike Wenzel receives speaker honoraria or is consultant for Accord, Johnsen&Johnsen, Pfizer, MSD, Astra Zeneca, Ipsen, Benedikt Hoeh receives speaker honoraria or is consultant for Johnsen&Johnsen and Ipsen, Thomas Steuber receives speaker honoraria or is consultant for Amgen, Astellas, Astra Zeneca, Bayer, Johnson & Johnson, MSD, Novartis, Pfizer, Proteomedics, Sanofi, Markus Graefen receives speaker honoraria or is consultant for Intuitive Surgical, Metronic, Ipsen, Astellas, Johnson & Johnson und Takeda, Tobias Maurer reports speaker fees from ABX, Astellas, Bayer, SanofiAventis and Phillips, consultant fees from ABX, Advanced Accelerator Applications International S.A., Ascenian, Astellas, Axiom, Blue Earth Diagnostics, GEMoAb, Novartis, ROTOP Pharma and Telix, and research funding from ABX, Brainlab, Intuitive Surgical and Telix, Felix Chun receives speaker honoraria or is consultant for Astellas, AstraZeneca, Bayer, Johnson & Johnson, Lumenis, Molecular Health, Olympus, Pfizer, Philipp Mandel receives speaker honoraria or is consultant for AMGEN, Astellas, AstraZeneca, Bayer, IPSEN, Johnson & Johnson, MSD, Novartis, Orion, Pfizer.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University Hospital Frankfurt, number: SUG-8-2024","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"756"}}